Skip to content
Bored Studies
RecruitingPhase 4

A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag

Liquidia Technologies, Inc. · NCT07759804

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–80 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 4
Target enrollment
20
US sites recruiting
1
Study start
September 2026
Record last updated
October 2, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) who switch from selexipag, a medicine taken by mouth, to treprostinil, a medicine breathed into the lungs.

Everyone who takes part will receive LIQ861. On the first study day, participants will stop taking selexipag and begin taking LIQ861 four times a day using a small handheld dry powder inhaler. The dose may be increased over time based on how well it is tolerated. Participants will take LIQ861 for 16 weeks.

The study will also look at whether switching to LIQ861 affects walking distance, a blood marker of heart strain, and symptoms reported by participants.

Being studied: LIQ861 (treprostinil) inhalation powder

Conditions: Pulmonary Arterial Hypertension (PAH)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Male or female 18 to 80 years of age
  • Documented findings on right heart catheterization consistent with a diagnosis of WHO Group 1 pulmonary arterial hypertension of one of the following subtypes: idiopathic PAH; heritable PAH; drug- or toxin-induced PAH; PAH associated with connective tissue disease; or PAH associated with simple congenital systemic-to-pulmonary shunts repaired at least 1 year previously
  • Receiving selexipag at any dose between 200 and 1600 mcg twice daily for at least 90 days, and willing and able to transition from selexipag to LIQ861 due to unsatisfactory clinical response or tolerability issues
  • May be receiving up to 2 additional approved non-prostacyclin oral PAH therapies at a stable dose and regimen, planned to continue unchanged for the duration of the study
  • New York Heart Association Functional Class II or III
  • Able to demonstrate correct use of the dry powder inhaler

Exclusion Criteria

  • Pulmonary hypertension in WHO Group 2, 3, 4, or 5, or a WHO Group 1 subtype not listed in the inclusion criteria
  • Clinically significant left-sided heart disease by echocardiography, including left ventricular ejection fraction ≤ 45%, left atrial volume index > 48 mL/m², or hemodynamically significant valvular disease
  • Symptomatic coronary artery disease within the previous 6 months
  • Prior atrial septostomy

Recruiting US locations

  • Southeastern Cardiology Associates

    Columbus, GA 31904

    Site contact: Hunter Champion, MD, PhD · 1-888-241-6906 · LiquidiaStudies@liquidia.com

Study contacts (from the official record)

  • Liquidia Point of Contact · 1-888-241-6906 · LiquidiaStudies@liquidia.com
All heart & blood pressure studies in Georgia →
A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary… (NCT07759804) | Bored Studies